Another piece in the overdiagnosis jigsaw puzzle

Affiliations

Editorial

Stephen W Duffy. BMJ Oncol. 2023.

. 2023 Dec 21;2(1):e000225.

doi: 10.1136/bmjonc-2023-000225. eCollection 2023.

¹ CCSPED, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.

No abstract available

Keywords: Breast cancer (female); Cancer screening.

Conflict of interest statement

Competing interests: None declared.

1. Puliti D, Duffy SW, Miccinesi G, et al. . Overdiagnosis in Mammographic screening for breast cancer in Europe: a literature review. J Med Screen 2012;19 Suppl 1:42–56. 10.1258/jms.2012.012082 - DOI - PubMed
1. de Gelder R, Heijnsdijk EAM, van Ravesteyn NT, et al. . Interpreting Overdiagnosis estimates in population-based Mammography screening. Epidemiol Rev 2011;33:111–21. 10.1093/epirev/mxr009 - DOI - PMC - PubMed
1. Chaltiel D, Hill C. Estimations of Overdiagnosis in breast cancer screening vary between 0% and over 50%: why BMJ Open 2021;11:e046353. 10.1136/bmjopen-2020-046353 - DOI - PMC - PubMed
1. Dempsey K, Costa DSJ, Brennan M, et al. . Benefits and harms of breast cancer screening Revisited: A large, retrospective Crosssectional study Quantifying treatment intensity in women with screen-detected versus Nonscreen-detected cancer in Australia and New Zealand. BMJ Oncology 2023.
1. Independent UK Panel on Breast Cancer Screening . The benefits and harms of breast cancer screening: an independent review. Lancet 2012;380:1778–86. 10.1016/S0140-6736(12)61611-0 - DOI - PubMed